Comments
Glenmark Pharmaceuticals on Saturday said its wholly-owned arm Glenmark Life Sciences has filed preliminary papers for an initial public offer (IPO) with market regulator SEBI.
Glenmark Life Sciences has filed a Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (Sebi) for an initial public offer, said a regulatory filing.
Also read: Glenmark Life Sciences plans ₹1,500-2,000 cr IPO
The offer comprises a fresh issue of up to ₹1,160 crore and an offer-for-sale (OFS) of up to 73,05,245 equity shares of ₹2 each of Glenmark Life Sciences Ltd, by Glenmark Pharmaceuticals Ltd, the filing said.
The board of directors of Glenmark Pharmaceuticals Ltd during its meeting on April 16 approved the OFS of up to 73,05,245 equity shares of ₹2 apiece as part of the IPO.
Also read: Glenmark appoints Yasir Rawjee as CEO of Glenmark Life Sciences
The IPO will be subject to market conditions, receipt of applicable approvals and other considerations, the filing said.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.